A Grade 4 spike in liver transaminases with increased total bilirubin that triggered FDA clinical holds in October 2025 now has a split outcome: the hold is lifted for Intellia’s MAGNITUDE-2 Phase 3 trial of nexiguran ziclumeran (nex-z) in hereditary ATTR with polyneuropathy (ATTRv-PN), while the cardiomyopathy study (MAGNITUDE) remains on hold. MAGNITUDE-2 will resume with enhanced liver safety monitoring and a modestly higher target enrollment, moving from approximately 50 to 60 patients. The study randomizes adults 1:1 to a single 55 mg infusion of nex-z or placebo, with primary endpoints of change in modified neuropathy impairment score and change in serum transthyretin (TTR) levels (NCT06672237).
The core development is a regulatory greenlight to restart the PN program under tighter guardrails, after the earlier safety event occurred in the ATTR-CM trial and triggered both holds via protocol-defined pausing criteria. For MAGNITUDE-2, Intellia has aligned with FDA on study modifications centered on more intensive liver lab surveillance. Engagement continues on the cardiomyopathy protocol, where the benefit-risk calculation is more complex given an older, comorbidity-heavy population. Interim Phase 1 data previously showed deep and durable TTR knockdown with nex-z, but the pivotal path will now hinge on demonstrating that editing intensity can be delivered without recurrent hepatic signals.
Strategically, separating PN from CM development reflects a pragmatic risk partitioning. ATTRv-PN offers a cleaner efficacy readout and fewer competing morbidity drivers, allowing the sponsor to re-establish a safety baseline and operational momentum while negotiating the CM pathway. The move also acknowledges competitive pressure: chronic RNAi silencers have established a strong foothold in PN with predictable safety profiles and are advancing in CM. Nex-z’s one-time in vivo CRISPR edit must now clear a higher bar on hepatic tolerability to justify its upfront risk for a potentially durable effect. The enrollment increase, while incremental, suggests a hedge to maintain statistical power under tighter monitoring windows and potential discontinuations.
For sites and CROs, the restart will require rapid reactivation: protocol amendments, re-consents, retraining on intensified LFT schedules, and potential adjustments to exclusion criteria around baseline hepatic function and concomitant medications. Central lab and DSMB cadence will tighten, demanding faster data flow and adjudication. Restart logistics also stress manufacturing and supply for a single-dose IV product, with site readiness for same-day infusion, observation, and subsequent frequent labs. Regulators are signaling a measured but constructive stance toward systemic CRISPR programs: operational rigor and real-time safety validation will dictate pacing more than headline efficacy.
The watch list now shifts to execution and signal stability. Near-term markers include first patient re-dosed post-hold, site reactivation velocity, and early safety snapshots under the enhanced monitoring schema. For MAGNITUDE, clarity on the remediation plan—whether via refined eligibility, dosing strategy, staggered dosing cohorts, or additional stopping rules—will indicate how much latitude FDA is prepared to grant in CM. Any recurrence of high-grade liver events could force dose reconsideration or compartmentalized development by phenotype. Conversely, clean hepatic safety alongside robust TTR reduction and functional gains in PN would de-risk the modality and influence regulatory expectations across in vivo editing programs. Timing of interim analyses, the durability of TTR suppression from a single 55 mg infusion, and the translation to clinically meaningful neuropathy improvements will determine whether the PN program can move decisively while CM awaits a negotiated path forward.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
